635 / 1726
Stage I high-intermediate risk (n = 427)
R
pelvic radiotherapy
vaginal brachytherapy
2
Nout et al, Lancet 2010
46 Gy / 23# / 5 wks
21 Gy / 3# / 2 wks
•
age > 60 and ≥50% invasion grd 1-2 or <50% invasion grd 3
•
FIGO 1988 stage 2A
•
TAH-BSO
without lymphadenectomy
PORTEC-2 trial (2002-2006)